JP2020511123A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020511123A5 JP2020511123A5 JP2019545292A JP2019545292A JP2020511123A5 JP 2020511123 A5 JP2020511123 A5 JP 2020511123A5 JP 2019545292 A JP2019545292 A JP 2019545292A JP 2019545292 A JP2019545292 A JP 2019545292A JP 2020511123 A5 JP2020511123 A5 JP 2020511123A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- sequence
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001413 amino acids Chemical group 0.000 claims description 78
- 239000008194 pharmaceutical composition Substances 0.000 claims description 42
- 101001043821 Homo sapiens Interleukin-31 Proteins 0.000 claims description 39
- 102100021596 Interleukin-31 Human genes 0.000 claims description 37
- 238000000034 method Methods 0.000 claims description 29
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 16
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 15
- 241000282326 Felis catus Species 0.000 claims description 14
- 241001465754 Metazoa Species 0.000 claims description 13
- 241000283073 Equus caballus Species 0.000 claims description 12
- 241000282465 Canis Species 0.000 claims description 10
- 239000003937 drug carrier Substances 0.000 claims description 10
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 claims description 10
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 10
- 241000282472 Canis lupus familiaris Species 0.000 claims description 9
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 8
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 8
- 229940068968 polysorbate 80 Drugs 0.000 claims description 8
- 229920000053 polysorbate 80 Polymers 0.000 claims description 8
- 239000000523 sample Substances 0.000 claims description 8
- 239000011780 sodium chloride Substances 0.000 claims description 8
- 229960002885 histidine Drugs 0.000 claims description 7
- 238000012575 bio-layer interferometry Methods 0.000 claims description 6
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 5
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 5
- 229960002216 methylparaben Drugs 0.000 claims description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 4
- 208000003251 Pruritus Diseases 0.000 claims description 4
- 229940024606 amino acid Drugs 0.000 claims description 4
- 238000004458 analytical method Methods 0.000 claims description 4
- 238000003119 immunoblot Methods 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 230000009131 signaling function Effects 0.000 claims description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 3
- -1 CD11α Proteins 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 3
- 239000003242 anti bacterial agent Substances 0.000 claims description 3
- 229960002668 sodium chloride Drugs 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 206010027654 Allergic conditions Diseases 0.000 claims description 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- 201000004624 Dermatitis Diseases 0.000 claims description 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 2
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims description 2
- 101000998146 Homo sapiens Interleukin-17A Proteins 0.000 claims description 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims description 2
- 101000599048 Homo sapiens Interleukin-6 receptor subunit alpha Proteins 0.000 claims description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 2
- 108010041012 Integrin alpha4 Proteins 0.000 claims description 2
- 108010065805 Interleukin-12 Proteins 0.000 claims description 2
- 102000013462 Interleukin-12 Human genes 0.000 claims description 2
- 108090000176 Interleukin-13 Proteins 0.000 claims description 2
- 102000003816 Interleukin-13 Human genes 0.000 claims description 2
- 102100033461 Interleukin-17A Human genes 0.000 claims description 2
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims description 2
- 108010065637 Interleukin-23 Proteins 0.000 claims description 2
- 102000013264 Interleukin-23 Human genes 0.000 claims description 2
- 102000004388 Interleukin-4 Human genes 0.000 claims description 2
- 108090000978 Interleukin-4 Proteins 0.000 claims description 2
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 claims description 2
- 229940122245 Janus kinase inhibitor Drugs 0.000 claims description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 2
- 239000012828 PI3K inhibitor Substances 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 206010039710 Scleroderma Diseases 0.000 claims description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 2
- 125000000539 amino acid group Chemical group 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims description 2
- 102000036639 antigens Human genes 0.000 claims description 2
- 108091007433 antigens Proteins 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 201000008937 atopic dermatitis Diseases 0.000 claims description 2
- 208000010668 atopic eczema Diseases 0.000 claims description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 2
- 239000012472 biological sample Substances 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 238000010494 dissociation reaction Methods 0.000 claims description 2
- 230000005593 dissociations Effects 0.000 claims description 2
- 102000045345 human IL31 Human genes 0.000 claims description 2
- 230000002209 hydrophobic effect Effects 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 238000001361 intraarterial administration Methods 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 238000007912 intraperitoneal administration Methods 0.000 claims description 2
- 238000007919 intrasynovial administration Methods 0.000 claims description 2
- 238000007913 intrathecal administration Methods 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000037361 pathway Effects 0.000 claims description 2
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 claims description 2
- 230000026731 phosphorylation Effects 0.000 claims description 2
- 238000006366 phosphorylation reaction Methods 0.000 claims description 2
- 239000003197 protein kinase B inhibitor Substances 0.000 claims description 2
- 108020003175 receptors Proteins 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 241000283086 Equidae Species 0.000 claims 2
- 102000043136 MAP kinase family Human genes 0.000 claims 1
- 108091054455 MAP kinase family Proteins 0.000 claims 1
- 230000006870 function Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 108010044426 integrins Proteins 0.000 claims 1
- 102000006495 integrins Human genes 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 238000009472 formulation Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 229940126638 Akt inhibitor Drugs 0.000 description 1
- 229940126560 MAPK inhibitor Drugs 0.000 description 1
- 238000002022 differential scanning fluorescence spectroscopy Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023076588A JP7716441B2 (ja) | 2017-02-24 | 2023-05-08 | 獣医用抗ｉｌ－３１抗体 |
| JP2025087766A JP2025138636A (ja) | 2017-02-24 | 2025-05-27 | 獣医用抗ｉｌ－３１抗体 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762463543P | 2017-02-24 | 2017-02-24 | |
| US62/463,543 | 2017-02-24 | ||
| PCT/US2017/023788 WO2018156180A1 (en) | 2017-02-24 | 2017-03-23 | Anti-il31 antibodies for veterinary use |
| USPCT/US2017/023788 | 2017-03-23 | ||
| PCT/US2018/017623 WO2018156367A1 (en) | 2017-02-24 | 2018-02-09 | Anti-il31 antibodies for veterinary use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023076588A Division JP7716441B2 (ja) | 2017-02-24 | 2023-05-08 | 獣医用抗ｉｌ－３１抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020511123A JP2020511123A (ja) | 2020-04-16 |
| JP2020511123A5 true JP2020511123A5 (https=) | 2021-03-18 |
| JP7277370B2 JP7277370B2 (ja) | 2023-05-18 |
Family
ID=63245488
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019545292A Active JP7277370B2 (ja) | 2017-02-24 | 2018-02-09 | 獣医用抗ｉｌ－３１抗体 |
| JP2023076588A Active JP7716441B2 (ja) | 2017-02-24 | 2023-05-08 | 獣医用抗ｉｌ－３１抗体 |
| JP2025087766A Pending JP2025138636A (ja) | 2017-02-24 | 2025-05-27 | 獣医用抗ｉｌ－３１抗体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023076588A Active JP7716441B2 (ja) | 2017-02-24 | 2023-05-08 | 獣医用抗ｉｌ－３１抗体 |
| JP2025087766A Pending JP2025138636A (ja) | 2017-02-24 | 2025-05-27 | 獣医用抗ｉｌ－３１抗体 |
Country Status (11)
| Country | Link |
|---|---|
| US (8) | US10093731B2 (https=) |
| EP (1) | EP3585429A4 (https=) |
| JP (3) | JP7277370B2 (https=) |
| KR (2) | KR102942127B1 (https=) |
| CN (2) | CN117603350A (https=) |
| AU (2) | AU2018224711B2 (https=) |
| BR (1) | BR112019017308A2 (https=) |
| CA (1) | CA3053525A1 (https=) |
| MA (1) | MA47609A (https=) |
| MX (1) | MX2024012304A (https=) |
| WO (1) | WO2018156180A1 (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102460040B1 (ko) | 2016-04-27 | 2022-11-01 | 애브비 인코포레이티드 | 항-il-13 항체를 이용한 il-13 활성이 유해한 질환의 치료 방법 |
| WO2018156180A1 (en) | 2017-02-24 | 2018-08-30 | Kindred Biosciences, Inc. | Anti-il31 antibodies for veterinary use |
| CA3054389A1 (en) * | 2017-03-07 | 2018-09-13 | Universitat Zurich | Treatment of pruritus in horses |
| AU2019236328B2 (en) | 2018-03-16 | 2025-10-09 | Zoetis Services Llc | Peptide vaccines against Interleukin-31 |
| WO2020132327A1 (en) * | 2018-12-19 | 2020-06-25 | The Trustees Of The University Of Pennsylvania | Use of cd2/5/7 knock-out anti-cd2/5/7 chimeric antigen receptor t cells against t cell lymphomas and leukemias |
| CA3147809A1 (en) * | 2019-08-29 | 2021-03-04 | Shyr Jiann Li | Anti-il31 antibodies for veterinary use |
| US20230053131A1 (en) | 2019-12-20 | 2023-02-16 | Intervet Inc. | Antibodies to canine interleukin-4 receptor alpha |
| MX2022007636A (es) * | 2019-12-20 | 2022-07-19 | Intervet Int Bv | Anticuerpos biespecificos caninizados y pares de union biespecificos para el tratamiento contra dermatitis atopica. |
| CN115697403A (zh) * | 2020-03-10 | 2023-02-03 | 迪赞纳生命科学公开有限公司 | Il-6/il-6r抗体的组合物及其使用方法 |
| WO2021212084A1 (en) * | 2020-04-17 | 2021-10-21 | Zoetis Services Llc | Feline antibody variants |
| CN115996949A (zh) * | 2020-04-17 | 2023-04-21 | 硕腾服务有限责任公司 | 犬抗体变异体 |
| EP4138914A4 (en) * | 2020-04-22 | 2024-05-22 | Elanco US Inc. | LONG-ACTING ANTI-IL31 ANTIBODIES FOR VETERINARY USE |
| EP4178977A1 (en) | 2020-07-10 | 2023-05-17 | Invetx, Inc. | Compositions for increasing half-life of a therapeutic agent in felines and methods of use |
| AU2021359068A1 (en) | 2020-10-15 | 2023-06-15 | Intervet International B.V. | Caninized antibodies to canine interleukin-31 receptor alpha |
| CA3199586A1 (en) * | 2020-11-23 | 2022-05-27 | Samantha J. Busfield | Antigen-binding molecules and uses thereof |
| BR112023016043A2 (pt) * | 2021-02-22 | 2023-12-05 | Zoetis Services Llc | Modelo de prurido induzido por il-31 de cavalo |
| MX2024002149A (es) | 2021-08-20 | 2024-03-08 | Intervet Int Bv | Proteinas de fusion para tratar la dermatitis atopica. |
| EP4448571A1 (en) | 2021-12-16 | 2024-10-23 | Intervet International B.V. | Caninized antibodies to canine interleukin-31 receptor alpha ii |
| EP4642795A2 (en) | 2022-12-27 | 2025-11-05 | Invetx, Inc. | Polypeptides with altered binding to neonatal fc receptor (fcrn) and methods of use |
| WO2024145280A2 (en) | 2022-12-27 | 2024-07-04 | Invetx, Inc. | Polypeptides with altered binding to neonatal fc receptor (fcrn) and methods of use |
| AU2024210302A1 (en) | 2023-01-20 | 2025-09-04 | Invetx, Inc. | Bispecific binding agents for use in companion animals |
| JP2026506599A (ja) | 2023-02-13 | 2026-02-25 | インターベット インターナショナル ベー． フェー． | イヌｉｌ－４に対するイヌ抗体 |
| EP4665459A1 (en) | 2023-02-13 | 2025-12-24 | Intervet International B.V. | Canine antibodies to canine il-13 |
| CN120865402A (zh) * | 2023-11-27 | 2025-10-31 | 宁波贝安生物科技有限公司 | 抗il-31的抗体及其用途 |
| CN118667001B (zh) * | 2024-07-16 | 2025-05-06 | 华中农业大学 | 一种抗犬il-31的单克隆抗体及其应用 |
| CN120209126B (zh) * | 2025-05-28 | 2025-09-16 | 中国医学科学院医学生物学研究所 | 人偏肺病毒单克隆抗体及其应用 |
Family Cites Families (120)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0628639B1 (en) | 1991-04-25 | 1999-06-23 | Chugai Seiyaku Kabushiki Kaisha | Reconstituted human antibody against human interleukin 6 receptor |
| JP3919830B2 (ja) | 1992-11-28 | 2007-05-30 | 財団法人化学及血清療法研究所 | 抗ネコヘルペスウイルス−１組換え抗体および該抗体をコードする遺伝子断片 |
| ATE335072T1 (de) | 1993-05-28 | 2006-08-15 | Scripps Research Inst | Methoden für inhibition der cd14-abhängigen zellaktivierung |
| EP1500329B1 (en) | 1996-12-03 | 2012-03-21 | Amgen Fremont Inc. | Human antibodies that specifically bind human TNF alpha |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| CN100455599C (zh) | 2000-03-03 | 2009-01-28 | 协和发酵工业株式会社 | 基因重组抗体及其抗体片段 |
| JP5290489B2 (ja) | 2001-11-08 | 2013-09-18 | アッヴィ・バイオセラピューティクス・インコーポレイテッド | Ｉｇｇ抗体の安定な液体医薬製剤 |
| EP1485126A4 (en) | 2001-12-21 | 2007-03-21 | Idexx Lab Inc | DOG IMMUNOGLOBULIN VARIABLE DOMAINS, DOG ANTIBODIES, AND METHOD FOR THEIR PRODUCTION AND USE |
| ATE401390T1 (de) | 2002-01-18 | 2008-08-15 | Zymogenetics Inc | Zytokin (zcytor17-ligand) |
| SI2301965T1 (sl) | 2002-10-16 | 2015-07-31 | Purdue Pharma L.P. | Protitelesa, ki vežejo celično- povezan CA 125 / O722P in metode uporabe le-teh |
| AR049390A1 (es) | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
| EP1671642A1 (en) | 2004-12-15 | 2006-06-21 | Universite D'angers | Compositions comprising (ant)agonists of oncostatin M (OSM), IL-31 and IFN-gamma for modulating keratinocyte migration and functions via a receptor containing OSMRbeta as a subunit, and applications thereof. |
| CA2594502A1 (en) | 2005-01-28 | 2006-08-03 | Zymogenetics Inc. | Homogeneous preparations of il-31 |
| JP2008530132A (ja) | 2005-02-14 | 2008-08-07 | ザイモジェネティクス， インコーポレイテッド | Ｉｌ−３１ｒａアンタゴニストを用いて皮膚障害を治療する方法 |
| US20060188500A1 (en) | 2005-02-14 | 2006-08-24 | Leung Donald Y | Methods of predicting therpeutic response in atopic dermatitis to IL-31 antagonists |
| CA2601400A1 (en) | 2005-03-19 | 2006-09-28 | Medical Research Council | Improvements in or relating to treatment and prevention of viral infections |
| WO2006105062A2 (en) | 2005-03-29 | 2006-10-05 | Verenium Corporation | Altered antibody fc regions and uses thereof |
| US8101183B2 (en) | 2005-05-06 | 2012-01-24 | Zymogentics, Inc. | Variable region sequences of IL-31 monoclonal antibodies |
| CN102321174B (zh) | 2005-05-06 | 2013-10-16 | 津莫吉尼蒂克斯公司 | Il-31单克隆抗体及使用方法 |
| RU2444528C2 (ru) | 2005-05-06 | 2012-03-10 | Займоджинетикс, Инк. | Моноклональные антитела против il-31 и способы применения |
| US20130216542A1 (en) | 2005-05-06 | 2013-08-22 | Zymogenetics, Inc. | Variable region sequences of il-31 monoclonal antibodies and methods of use |
| CN1896229A (zh) | 2005-06-29 | 2007-01-17 | 北京天广实生物技术有限公司 | 一种新型抗cd20嵌合抗体的制备及其用途 |
| CA2626783A1 (en) | 2005-10-21 | 2007-05-03 | Merck & Co., Inc. | Anti-addl monoclonal antibody and use thereof |
| WO2007133816A2 (en) | 2006-01-10 | 2007-11-22 | Zymogenetics, Inc. | Methods of treating pain and inflammation in neuronal tissue using il-31ra and osmrb antagonists |
| ES2673822T3 (es) | 2006-07-18 | 2018-06-25 | Sanofi | Anticuerpo antagonista contra EphA2 para el tratamiento de cáncer |
| DK2594586T3 (en) | 2006-09-01 | 2014-11-17 | Zymogenetics Inc | Monoclonal il-31 antibodies and methods of use thereof |
| CA2914170C (en) | 2006-09-08 | 2018-10-30 | Abbvie Bahamas Ltd. | Interleukin-13 binding proteins |
| CN101588816B (zh) | 2006-10-19 | 2013-06-19 | Csl有限公司 | 白介素-13受体α1的高亲和性抗体拮抗物 |
| US7799323B2 (en) | 2007-01-10 | 2010-09-21 | Zymogenetics, Inc. | Methods of using IL-31 to treat airway hyper-responsiveness and asthma |
| JOP20080381B1 (ar) | 2007-08-23 | 2023-03-28 | Amgen Inc | بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9) |
| EP2796466B1 (en) | 2007-12-07 | 2017-11-22 | ZymoGenetics, Inc. | Humanized antibody molecules specific for IL-31 |
| KR102057826B1 (ko) | 2008-04-11 | 2019-12-20 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복 결합하는 항원 결합 분자 |
| JP4884570B2 (ja) | 2008-08-20 | 2012-02-29 | ファイザー・インク | ピロロ［２，３−ｄ］ピリミジン化合物 |
| EP2725037A1 (en) | 2008-09-04 | 2014-04-30 | Vet Therapeutics, Inc. | Monoclonal antibodies binding canine CD20 |
| PL2365828T3 (pl) | 2008-11-07 | 2015-04-30 | Galaxy Biotech Llc | Przeciwciała monoklonalne swoiste dla receptora 2 czynnika wzrostu fibroblastów |
| WO2011065935A1 (en) | 2009-11-24 | 2011-06-03 | Cornell University | Methods for monoclonal antibody production |
| US20110287454A1 (en) | 2008-11-25 | 2011-11-24 | Cornell University | Methods for monoclonal antibody production |
| AU2013203075A1 (en) | 2008-11-28 | 2013-05-02 | Abbott Laboratories | Stable antibody compositions and methods for stabilizing same |
| US20110165063A1 (en) | 2009-01-29 | 2011-07-07 | Abbott Laboratories | Il-1 binding proteins |
| WO2010117448A2 (en) | 2009-04-05 | 2010-10-14 | Provenance Biopharmaceuticals Corp. | Chimeric immunocytokines and methods of use thereof |
| RU2012101995A (ru) | 2009-06-22 | 2013-07-27 | Пептселл Лимитед | Фармацевтический агент |
| AU2010306677B2 (en) | 2009-10-15 | 2013-05-23 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
| JO3244B1 (ar) | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
| CN103037900B (zh) | 2010-02-24 | 2016-04-06 | 伊缪诺金公司 | 叶酸受体1抗体与免疫缀合物以及其用途 |
| KR101539684B1 (ko) | 2010-05-14 | 2015-07-27 | 애브비 인코포레이티드 | Ｉｌ－１ 결합 단백질 |
| TWI560199B (en) | 2010-08-31 | 2016-12-01 | Sanofi Sa | Peptide or peptide complex binding to α2 integrin and methods and uses involving the same |
| US9255925B2 (en) | 2010-10-20 | 2016-02-09 | Medical Diagnostic Laboratories, Llc | ELISA detection of urine DEK to predict and diagnose bladder cancer in humans |
| PH12016502073B1 (en) | 2010-11-17 | 2024-04-05 | Chugai Pharmaceutical Co Ltd | Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii |
| AR084210A1 (es) | 2010-12-08 | 2013-05-02 | Abbott Lab | PROTEINAS DE UNION AL TNF-a |
| WO2012088094A2 (en) | 2010-12-21 | 2012-06-28 | Abbott Laboratories | Il-1 binding proteins |
| SMT201800269T1 (it) | 2011-04-25 | 2018-07-17 | Daiichi Sankyo Co Ltd | Anticorpo anti-b7-h3 |
| AR086250A1 (es) | 2011-05-05 | 2013-11-27 | Hoffmann La Roche | Polipeptido de fusion presentador de una secuencia de aminoacidos y utilizacion del mismo |
| GB2504887B (en) | 2011-05-06 | 2016-02-03 | Nvip Pty Ltd | Anti-Nerve growth factor antibodies and methods of preparing and using the same |
| KR102101806B1 (ko) | 2011-05-19 | 2020-04-20 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 항-인간-her3 항체 및 이의 용도 |
| US8790651B2 (en) | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| KR20130036993A (ko) | 2011-10-05 | 2013-04-15 | 삼성전자주식회사 | ｃ-Ｍｅｔ의 ＳＥＭＡ 도메인 내의 에피토프에 특이적으로 결합하는 항체 |
| JO3532B1 (ar) * | 2013-03-13 | 2020-07-05 | Regeneron Pharma | الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها |
| WO2014152195A1 (en) | 2013-03-15 | 2014-09-25 | Regeneron Pharmaceuticals, Inc. | Il-33 antagonists and uses thereof |
| PL2970497T3 (pl) | 2013-03-15 | 2018-05-30 | Bayer Healthcare Llc | Warianty przeciwciał anty-TFPI z różnicowym wiązaniem w zakresie pH dla poprawy farmakokinetyki |
| KR102343212B1 (ko) | 2013-03-27 | 2021-12-23 | 세다르스-신나이 메디칼 센터 | Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한 섬유증 및 염증의 완화 및 반전 |
| EP3003350B1 (en) | 2013-05-27 | 2018-02-21 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Targeted modulation of macrophages |
| SI3456743T1 (sl) | 2013-05-30 | 2022-01-31 | Kiniksa Pharmaceuticals, Ltd. | Proteini, ki vežejo antigen receptorja onkostatina M |
| TW201537175A (zh) | 2013-06-28 | 2015-10-01 | Chugai Pharmaceutical Co Ltd | 預測罹患具皮膚搔癢之疾病的患者對ｉｌ－３１拮抗劑之治療的反應之方法 |
| EP3017048A4 (en) | 2013-07-01 | 2017-05-17 | University of Maryland, College Park | Fc coupled compositions and methods of their use |
| WO2015042596A1 (en) | 2013-09-23 | 2015-03-26 | Kindred Biosciences, Inc | Treatment of atopic dermatitis in non-human animals |
| CN105705517A (zh) | 2013-11-07 | 2016-06-22 | 诺和诺德股份有限公司 | 用于治疗凝血障碍的新方法和抗体 |
| WO2015086830A1 (en) | 2013-12-13 | 2015-06-18 | Delenex Therapeutics Ag | Skin penetrating polypeptides |
| CN103965357B (zh) | 2013-12-31 | 2016-08-17 | 嘉和生物药业有限公司 | 一种抗人rankl抗体 |
| TWI694836B (zh) * | 2014-05-16 | 2020-06-01 | 英商葛蘭素史克智慧財產管理有限公司 | 抗體調配物 |
| JP7020909B2 (ja) | 2014-07-25 | 2022-02-16 | シトムクス セラピューティクス，インコーポレイティド | 抗－ｃｄ３抗体、活性化可能抗－ｃｄ３抗体、多重特異的抗－ｃｄ３抗体、多重特異的活性化可能抗－ｃｄ３抗体、及びそれらの使用方法 |
| CN104403004B (zh) | 2014-11-24 | 2017-10-13 | 苏州丁孚靶点生物技术有限公司 | 抗体‑干扰素异二聚体的制备和用途 |
| JP2018504911A (ja) | 2015-01-29 | 2018-02-22 | ネックスヴェット オーストラリア プロプライエタリー リミテッド | 治療及び診断剤 |
| CN104710528B (zh) * | 2015-03-13 | 2019-02-15 | 西北农林科技大学 | 一种特异性结合PRRS病毒非结构蛋白Nsp9纳米抗体及其应用 |
| KR20170134748A (ko) | 2015-04-14 | 2017-12-06 | 추가이 세이야쿠 가부시키가이샤 | Il-31 안타고니스트를 유효 성분으로서 함유하는 아토피성 피부염의 예방용 및/또는 치료용 의약 조성물 |
| RU2749113C2 (ru) | 2015-04-22 | 2021-06-04 | Куревак Аг | Содержащая рнк композиция для лечения опухолевых заболеваний |
| WO2015151079A2 (en) | 2015-06-20 | 2015-10-08 | Hangzhou Dac Biotech Co, Ltd | Auristatin analogues and their conjugates with cell-binding molecules |
| WO2017025698A1 (en) | 2015-08-11 | 2017-02-16 | Queen Mary University Of London | Bispecific, cleavable antibodies |
| TW201729810A (zh) | 2015-10-26 | 2017-09-01 | 札爾科製藥公司 | 嘧啶組成物、其超純組成物及鹽類、製造彼之方法、及使用彼於治療組織胺h4受體(h 4 )仲介之疾病與病情之方法 |
| AU2017239637A1 (en) * | 2016-03-29 | 2018-11-15 | Obi Pharma, Inc. | Antibodies, pharmaceutical compositions and methods |
| CN109789201B (zh) | 2016-04-15 | 2023-06-16 | 伊穆奈克斯特股份有限公司 | 抗人vista抗体及其用途 |
| CA3016172C (en) | 2016-04-20 | 2024-03-12 | Hangzhou Dac Biotech Co., Ltd | Derivatives of amanita toxins and their conjugation to a cell binding molecule |
| WO2018073185A1 (en) | 2016-10-17 | 2018-04-26 | Vetoquinol Sa | Modified antibody constant region |
| CA3042442C (en) | 2016-11-14 | 2024-01-02 | Hangzhou Dac Biotech Co., Ltd | Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses of such conjugates with the linkers |
| TWI857389B (zh) | 2016-12-01 | 2024-10-01 | 美商再生元醫藥公司 | 治療發炎症狀的方法 |
| WO2018156367A1 (en) | 2017-02-24 | 2018-08-30 | Kindred Biosciences, Inc. | Anti-il31 antibodies for veterinary use |
| WO2018156180A1 (en) * | 2017-02-24 | 2018-08-30 | Kindred Biosciences, Inc. | Anti-il31 antibodies for veterinary use |
| KR102655301B1 (ko) | 2017-04-06 | 2024-04-08 | 항저우 디에이씨 바이오테크 씨오, 엘티디 | 비스-링키지를 사용한 세포독성 약물의 접합 |
| AU2018250641B2 (en) | 2017-04-11 | 2025-03-13 | Inhibrx Biosciences, Inc. | Multispecific polypeptide constructs having constrained CD3 binding and methods of using the same |
| US11970526B2 (en) | 2017-04-21 | 2024-04-30 | Elanco Us Inc. | IL4/IL13 receptor molecule for veterinary use |
| EP3483180A1 (en) | 2017-11-14 | 2019-05-15 | Affilogic | Multi specific molecules |
| MX2020006105A (es) | 2017-12-11 | 2020-11-09 | Ubi Ip Holdings | Inmunógenos peptídicos de il-31 y formulaciones de estos para el tratamiento y/o la prevención de la dermatitis atópica. |
| JP7262817B2 (ja) | 2017-12-31 | 2023-04-24 | ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ． | 分岐連結体を備えたチューブリシン類縁体の共役体 |
| CA3093539A1 (en) | 2018-03-16 | 2019-09-19 | Zoetis Services Llc | Interleukin-31 monoclonal antibodies for veterinary use |
| WO2019183449A1 (en) | 2018-03-23 | 2019-09-26 | North Carolina State University | Methods and compositions for allergic disorders |
| BR112020020604A2 (pt) | 2018-04-11 | 2021-01-12 | Inhibrx, Inc. | Construções de polipeptídeo multiespecífico tendo ligação restrita de cd3 e métodos e usos relacionados |
| EA202190189A1 (ru) | 2018-07-05 | 2021-04-16 | Ханчжоу Дэк Биотек Ко., Лтд | Сшитое производное димера пирролобензодиазепина (pbd) и его конъюгаты |
| WO2020056393A1 (en) | 2018-09-14 | 2020-03-19 | Kindred Biosciences, Inc. | Anti-il4 receptor antibodies for veterinary use |
| BR112021006160A2 (pt) | 2018-10-12 | 2021-06-29 | Hangzhou Dac Biotech Co., Ltd | composto conjugado, célula tumoral, composição farmacêutica, e, agentes sinérgicos |
| CN113194984A (zh) | 2018-10-18 | 2021-07-30 | 金德雷德生物科学股份有限公司 | 兽用的与新生儿Fc受体(FcRn)结合改变的Fc变体 |
| US12428466B2 (en) | 2018-10-25 | 2025-09-30 | Elanco Us Inc. | IL4/IL13 receptor molecule for veterinary use |
| WO2020092015A1 (en) | 2018-11-02 | 2020-05-07 | University Of Rochester | Therapeutic mitigation of epithelial infection |
| MX2021007680A (es) | 2018-12-27 | 2021-10-13 | Kindred Biosciences Inc | Variantes de igg fc para uso veterinario. |
| US11542333B2 (en) | 2019-01-03 | 2023-01-03 | Invetx, Inc. | Compositions for increasing half-life of a therapeutic agent in canines and methods of use |
| KR20250100803A (ko) | 2019-01-31 | 2025-07-03 | 항저우 디에이씨 바이오테크 씨오, 엘티디 | 분지형 링커를 갖는 아마니타 독소의 접합체 |
| CN113597328B (zh) | 2019-03-21 | 2025-10-31 | 瑞泽恩制药公司 | 用于治疗过敏症的il-4/il-13途径抑制剂和浆细胞消融的组合 |
| MY204342A (en) | 2019-03-25 | 2024-08-24 | Alteogen Inc | Pharmaceutical composition, comprising human hyaluronidase ph20 variant and drug, for subcutaneous injection |
| CN114040781A (zh) | 2019-06-24 | 2022-02-11 | 杭州多禧生物科技有限公司 | Tubulysin衍生物与细胞结合分子偶联物的制剂配方 |
| MX2021015887A (es) | 2019-06-24 | 2022-03-22 | Hangzhou Dac Biotech Co Ltd | Un conjugado de un agente citotóxico y una molécula de unión a células con enlazadores ramificados. |
| CA3147809A1 (en) | 2019-08-29 | 2021-03-04 | Shyr Jiann Li | Anti-il31 antibodies for veterinary use |
| MX2022004919A (es) | 2019-12-13 | 2022-05-16 | Sichuan Kelun Biotech Biopharmaceutical Co Ltd | Anticuerpo anti-linfopoyetina estromal timica (tslp) y sus usos. |
| MX2022007636A (es) | 2019-12-20 | 2022-07-19 | Intervet Int Bv | Anticuerpos biespecificos caninizados y pares de union biespecificos para el tratamiento contra dermatitis atopica. |
| US20230348577A1 (en) | 2020-02-19 | 2023-11-02 | Adivo Gmbh | Modified fc regions |
| AU2021238320A1 (en) | 2020-03-18 | 2022-09-22 | Elanco Us Inc. | Anti-IL4 receptor antibodies for veterinary use |
| CN115996949A (zh) | 2020-04-17 | 2023-04-21 | 硕腾服务有限责任公司 | 犬抗体变异体 |
| EP4138914A4 (en) | 2020-04-22 | 2024-05-22 | Elanco US Inc. | LONG-ACTING ANTI-IL31 ANTIBODIES FOR VETERINARY USE |
| BR112022021204A2 (pt) | 2020-04-22 | 2022-12-06 | Kindred Biosciences Inc | Polipeptídeos, proteínas heterodiméricas, ácido nucleico, células hospedeiras, método, composição farmacêutica e método de tratamento de uma espécie de animal de companhia, métodos para reduzir a atividade de sinalização de il13 e/ou il4 e para detectar il13 ou il4 em uma amostra |
| IL299001A (en) | 2020-06-19 | 2023-02-01 | Hangzhou Dac Biotech Co Ltd | Pairings of a cell-binding molecule with camptocin analogs |
| EP4178977A1 (en) | 2020-07-10 | 2023-05-17 | Invetx, Inc. | Compositions for increasing half-life of a therapeutic agent in felines and methods of use |
| GB202012331D0 (en) | 2020-08-07 | 2020-09-23 | Petmedix Ltd | Therapeutic antibodies |
| US20230391878A1 (en) | 2020-09-01 | 2023-12-07 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition for prevention and/or treatment of dialysis pruritus containing il-31 antagonist as active ingredient |
-
2017
- 2017-03-23 WO PCT/US2017/023788 patent/WO2018156180A1/en not_active Ceased
- 2017-03-23 US US15/467,464 patent/US10093731B2/en active Active
- 2017-12-15 US US15/844,142 patent/US10150810B2/en active Active
-
2018
- 2018-02-09 CN CN202311589839.9A patent/CN117603350A/zh active Pending
- 2018-02-09 KR KR1020247015851A patent/KR102942127B1/ko active Active
- 2018-02-09 CN CN201880026436.4A patent/CN110769851B/zh active Active
- 2018-02-09 AU AU2018224711A patent/AU2018224711B2/en active Active
- 2018-02-09 BR BR112019017308-0A patent/BR112019017308A2/pt active Search and Examination
- 2018-02-09 EP EP18756690.6A patent/EP3585429A4/en active Pending
- 2018-02-09 US US16/488,045 patent/US11673946B2/en active Active
- 2018-02-09 KR KR1020197025631A patent/KR20190127703A/ko not_active Ceased
- 2018-02-09 CA CA3053525A patent/CA3053525A1/en active Pending
- 2018-02-09 MA MA047609A patent/MA47609A/fr unknown
- 2018-02-09 JP JP2019545292A patent/JP7277370B2/ja active Active
- 2018-11-09 US US16/186,013 patent/US20190169285A1/en not_active Abandoned
-
2019
- 2019-08-21 MX MX2024012304A patent/MX2024012304A/es unknown
-
2020
- 2020-09-30 US US17/039,495 patent/US11697683B2/en active Active
-
2023
- 2023-05-03 US US18/311,777 patent/US12448438B2/en active Active
- 2023-05-08 JP JP2023076588A patent/JP7716441B2/ja active Active
- 2023-05-24 US US18/322,737 patent/US12435132B2/en active Active
-
2025
- 2025-02-19 AU AU2025201182A patent/AU2025201182A1/en active Pending
- 2025-05-27 JP JP2025087766A patent/JP2025138636A/ja active Pending
- 2025-09-10 US US19/325,042 patent/US20260092107A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020511123A5 (https=) | ||
| JP7589269B2 (ja) | 抗ｂｃｍａ重鎖のみ抗体 | |
| JP7716441B2 (ja) | 獣医用抗ｉｌ－３１抗体 | |
| JP7303126B2 (ja) | 抗ｂｃｍａ重鎖のみ抗体 | |
| AU2018288803B2 (en) | Anti-BCMA heavy chain-only antibodies | |
| JP5771140B2 (ja) | 治療用のｇｍ−ｃｓｆおよびｉｌ−１７阻害剤 | |
| JPWO2021216810A5 (https=) | ||
| JPWO2021041972A5 (https=) |